Illumina wants a greater part of the reproductive-health market, says CEO Jay Flatley.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
Complete Genomics' race to lower the costs of DNA sequencing didn't yield business success.
A monkey study suggests that neural implants could one day help brain-damaged patients perform specific cognitive tasks.
The rodent recovery spurs hope that humans could one day benefit from similar treatments.
The demonstration in rodents could one day be combined with cochlear implants to treat more people than is currently possible.
IBM's Blue Gene supercomputer uncovers a novel drug interaction site.
A biotech company called Cerulean says its nanoparticle-delivered cancer drugs are better at attacking tumors.
The technique would retrain cells that typically don't respond to light.
Although Eli Lilly's anti-amyloid compound fails to slow decline in two large trials, patients with mild forms of the disease show some benefit
Researchers use DNA sequencing to identify the molecular basis of a patient's unique but beneficial response to an experimental cancer drug.